Global Hyperkalemia Treatment Market Growth 2023-2029
Hyperkalemia is a diseases in which levels of potassium are higher than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating its excretion as well as its intake. A person is prone to develop hyperkalemia when the consumption of potassium exceeds that of kidneys’ potential to excrete it. The right amount of potassium and sodium in the body play a vital role in normal functioning of the myocardium.
Hyperkalemia can occur due to congestive heart failure, chronic kidney disease, or diabetic kidney disease. The condition can also occur when a patient receives renin-angiotensin-aldosterone system inhibitors (RAAS) in kidney disease. Abnormal levels of potassium can lead to irregular heartbeats, which can be fatal. Hyperkalemia is diagnosed by kidney functioning test, creatinine blood test, blood tests, and glucose monitoring.
LPI (LP Information)' newest research report, the “Hyperkalemia Treatment Industry Forecast” looks at past sales and reviews total world Hyperkalemia Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Hyperkalemia Treatment sales for 2023 through 2029. With Hyperkalemia Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hyperkalemia Treatment industry.
This Insight Report provides a comprehensive analysis of the global Hyperkalemia Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hyperkalemia Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Hyperkalemia Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hyperkalemia Treatment and breaks down the forecast by type, by distribution channel, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hyperkalemia Treatment.
The global Hyperkalemia Treatment market size is projected to grow from US$ 528.3 million in 2022 to US$ 2086.4 million in 2029; it is expected to grow at a CAGR of 2086.4 from 2023 to 2029.
The main manufacturers of Global Hyperkalemia Treatment include Vifor Pharma, Astrazeneca, etc. These top two manufacturers hold a market share about 50%. North America and Europe are the major producing regions in the world.
This report presents a comprehensive overview, market shares, and growth opportunities of Hyperkalemia Treatment market by product type, distribution channel, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Patiromer
Sodium Zirconium Cyclosilicate
Segmentation by distribution channel
Hospital Pharmacy
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vifor Pharma
Astrazeneca
Sanofi
CMP Pharma
Belcher Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hyperkalemia Treatment market?
What factors are driving Hyperkalemia Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hyperkalemia Treatment market opportunities vary by end market size?
How does Hyperkalemia Treatment break out type, distribution channel?
What are the influences of COVID-19 and Russia-Ukraine war?
Please note: The report will take approximately 2 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook